Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 9, 2006

View Archived Issues

Millennium profiles recent highlights

Antiangiogenic effects of CTCE-9908 could explain its antimetastatic properties

Gilead Sciences: Q4 review

Update on H5N1 vaccine development projects

IND cleared for phase I study of Tramadol ER

BioSante awarded subcontract for recombinant Factor IX formulation work

New sugar-cholestanol with anticancer activity

Phase I/II study shows efficacy of cell therapy for nasopharyngeal carcinoma

Heparan sulfate mimetics tested against dengue virus and flaviviral encephalitis

Therapeutic potential of anthrax lethal toxin in Kaposi's sarcoma

Ono profiles progress of recent months

APEX-AMI pexelizumab trial set to conclude

TRO-19622 completes phase I trials

Solbec prepares for phase II trials of Coramsine

Akzo Nobel to create two independent companies

PBT-2 completes phase I program

European Commission approval for Novartis' acquisition of Chiron

Fortovase discontinued, Invirase preferred option

MC4 antagonist/serotonin transport inhibitor for stress-related anxiety and depression

New Abilify options now available

New treatments for hepatitis C described in recent Boehringer Ingelheim patent

Novel agents imparted for inflammatory disorders

Potent targeting of c-Fos enhances the antiosteogenic activity of new vitamin D analogues

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Aug. 3, 2026.
Tuojie Biotech (Shanghai) synthesizes new SARM1 inhibitors
BioWorld Science
Tuojie Biotech (Shanghai) Co. Ltd. has prepared and tested NAD(+) hydrolase SARM1 (SAMD2; MyD88-5) inhibitors found to be potentially useful for the treatment of...
Death in Chinese gene-editing trial exposes ethical fault lines
BioWorld
The death of a 6-year-old girl after receiving an experimental brain-directed gene-editing therapy at the Xinhua Hospital in Shanghai has reopened debate over how...
Seed funding at Adjuvia to treat mitochondrial dysfunction
BioWorld Science
Adjuvia Therapeutics Inc. has closed a $8 million series seed financing round to advance its work developing therapeutics to treat mitochondrial dysfunction and...
Replimune’s RP-1 for melanoma wins over FDA adcom
BioWorld
Following two complete response letters in the past year, Replimune Group Inc.’s RP-1 (suvolimogene oderparepvec) for unresectable metastatic cutaneous melanoma...